Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2015

Courtney KD, Manola JB, Elfiky AA, Ross R, Oh WK, Yap JT, et al. A phase I study of everolimus and docetaxel in patients with castration-resistant prostate cancer. Clin Genitourin Cancer. 2015;13(2):113-23.

Mathieu R, Klatte T, Margulis V, Karam JA, Rouprêt M, Seitz C, et al. Survivin is not an independent prognostic factor for patients with upper tract urothelial carcinoma: a multi-institutional study. Urol Oncol. 2015;33(11):495.e15-22.

2014

Preston MA, Wilson KM, Markt SC, Ge R, Morash C, Stampfer MJ, et al. 5α-Reductase inhibitors and risk of high-grade or lethal prostate cancer. JAMA Intern Med. 2014;174(8):1301-7.

Selvarajah S, Pyne S, Chen E, Sompallae R, Ligon AH, Nielsen GP, et al. High-resolution array CGH and gene expression profiling of alveolar soft part sarcoma. Clin Cancer Res. 2014;20(6):1521-30.

Vogel MJ, Xie L, Guan H, Tooze RM, Maier T, Kostezka U, et al. FOXO1 repression contributes to block of plasma cell differentiation in classical Hodgkin lymphoma. Blood. 2014;124(20):3118-29.

Gao D, Vela I, Sboner A, Iaquinta PJ, Karthaus WR, Gopalan A, et al. Organoid cultures derived from patients with advanced prostate cancer. Cell. 2014;159(1):176-187.

Goyal A, Yang B. Cytologic features of stratified mucin producing intraepithelial lesion of the cervix--a case report. Diagn Cytopathol. 2014;42(9):792-7.

Ferrante M, Khan A, Fan C, Jelloul FZ. Schwannoma of the cervical esophagus. Rare Tumors. 2014;6(2):5361.

Yigit N, Geyer JT. Bone marrow metastasis of prostatic adenocarcinoma with post-treatment foamy-like changes: A diagnostic pitfall. Can Urol Assoc J. 2014;8(11-12):E941-3.

Taplin M-, Montgomery B, Logothetis CJ, Bubley GJ, Richie JP, Dalkin BL, et al. Intense androgen-deprivation therapy with abiraterone acetate plus leuprolide acetate in patients with localized high-risk prostate cancer: results of a randomized phase II neoadjuvant study. J Clin Oncol. 2014;32(33):3705-15.